Clinical trials: Adenovirus Disease
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor, Solid Organ Transplantation Recipient
- Trial name
- NCT03665675
- Testing
- Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes, Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sumithira Vasu
CMV, AdV Infection
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.
- Conditions
- CMV, AdV Infection, AdV Reactivation, Adenovirus
- Trial name
- NCT07225972
- Testing
- Standard of Care Antiviral medications, Viral CTLs
- Where
- 2 sites in United States
- Volunteers
- 138 people
- Sponsor
- New York Medical College
Esophageal Neoplasms
Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma
This study is a randomized, double-blinded assessment of biologic efficacy of AdcuCD40L. The individuals enrolled in this study will be individuals with biopsy proven resectable esophageal carcinoma.
- Trial name
- cd40 (NCT00504322)
- Testing
- AdcuCD40L
- Sponsor
- Weill Medical College of Cornell University
Adenoviral Infection
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection.
- Trial name
- NCT03160339
- Testing
- PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
HIV Infections
"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection
This study will determine the safety and side effects of two experimental HIV vaccines given in a "prime-boost" schedule. It will also monitor participants for the social impact of being in an HIV vaccine study (e.g., problems…
- Trial name
- NCT00109629
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Brain Injuries, Traumatic
Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.
- Trial name
- MOBI-1 (NCT04893837)
- Testing
- Standard care plus infrascans
- Where
- 2 sites in United States
- Volunteers
- 399 people
- Sponsor
- University of Alabama at Birmingham
Melanoma (Skin)
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir.
- Trial name
- NCT00005057
- Testing
- adenovirus RSV-TK, ganciclovir
- Where
- 3 sites in United States
- Sponsor
- National Human Genome Research Institute (NHGRI)
Severe Haemophilia A
Gene Therapy Study in Severe Haemophilia A Patients (270-201)
This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, dose escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec (an Adenovirus-Associated Virus based gene therapy…
- Trial name
- NCT02576795
- Testing
- valoctocogene roxaparvovec
- Where
- 5 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- BioMarin Pharmaceutical
Hepatocellular Carcinoma (HCC)
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
Indication: Hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) stage C. Study Objectives: This study aims to use a prospective single-center single-arm pilot approach to preliminarily obtain data on…
- Trial name
- NCT06685354
- Testing
- hepatic arterial infusion of recombinant human type 5 adenovirus
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Henan Cancer Hospital
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray
Randomized, double-blind, placebo-controlled trial to evaluate safety and immunogenicity of intranasal "Gam-COVID-Vak" combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus.
- Trial name
- SPRAY (NCT05248373)
- Testing
- Gam-COVID-Vac
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
End Stage Renal Disease
Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence
Patients in renal failure on hemodialysis depend on adequate and sustained vascular access. This can be achieved by surgical placement of a synthetic polytetrafluoroethylene (PTFE) graft.
- Trial name
- AdV-VANTAGE (NCT00895479)
- Testing
- Graft placement surgery plus Trinam therapy
- Where
- 12 sites in United States
- Volunteers
- 250 people
- Sponsor
- Ark Therapeutics Ltd
AdV Infection, EBV Infection
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality.
- Conditions
- AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
- Trial name
- TRACE (NCT04832607)
- Testing
- Multivirus (CMV, EBV, AdV)-specific T cells
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Tobias Feuchtinger
Malignant Pleural Effusion
Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion
Objective of this study is to investigate of efficacy and safety of recombinant adenoviral human p53 Gene (rAd-p53) in treatment of malignant pleural effusion, compared to cisplatin.
- Trial name
- NCT02429726
- Testing
- rAdp53, Cisplatin, rAdp53 plus cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03330197
- Testing
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alaunos Therapeutics
Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
The purpose of this study is to learn if a vaccine made from the patient's own tumor cells, then genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), will delay or stop the growth of the…
- Conditions
- Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT00258687
- Testing
- GVAX
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Hepatocellular Carcinoma
Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
Sorafenib, as a first-line treatment for patients with advanced HCC, can significantly prolong the overall survival rate of patients.
- Trial name
- NCT05113290
- Testing
- Recombinant Human Adenovirus Type 5 injection, Sorafenib
- Where
- 4 sites in China
- Volunteers
- 66 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Breast Cancer
Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer
The purpose of this trial is to test the safety of a vaccine made from a patient's own breast cancer cells, and determine if this vaccine will delay or stop the growth of the cancer.
- Trial name
- NCT00880464
- Testing
- Autologous, Lethally Irradiated Breast Cancer Cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Primary Peritoneal Cancer
Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients
The primary purpose of this study is to determine the maximally tolerated dose and spectrum of toxicities encountered with intraperitoneal delivery of a RGD modified conditionally replicative adenovirus (Ad5-Delta 24RGD) in…
- Trial name
- Ad5Delta24RGD (NCT00562003)
- Testing
- Tenckhoff Catheter placement, Ad5-delta24RGD
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Alabama at Birmingham
Adenoviral Keratoconjunctivitis
Adenovirus Keratoconjunctivitis and Ophtalmology
Adenovirus conjunctivitis is an epidemic disease registered as a common occupational disease for ophthalmologists and orthoptists. It can leave corneal sequelae even several years after infection.
- Trial name
- ADV-OPH (NCT04417244)
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
X-Linked Chronic Granulomatous Disease
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
The goal of this clinical trial is to evaluate the safety and potential efficacy of the EN-374 treatment regimen and identify a dose level for further evaluation in participants with x-linked chronic granulomatous disease.
- Trial name
- NCT06876363
- Testing
- EN-374
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Ensoma